Chen R - Search Results

1

Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE.

Mei MG, Lee HJ, Palmer JM, Chen R, Tsai NC, Chen L, McBride K, Smith DL, Melgar I, Song JY, Bonjoc KJ, Armenian S, Nwangwu M, Lee PP, Zain J, Nikolaenko L, Popplewell L, Nademanee A, Chaudhry A, Rosen S, Kwak L, Forman SJ, Herrera AF. Mei MG, et al. Among authors: chen l, chen r. Blood. 2022 Jun 23;139(25):3605-3616. doi: 10.1182/blood.2022015423. Blood. 2022. PMID: 35316328 Free PMC article. Clinical Trial.

2

Reduced intensity allogeneic hematopoietic cell transplantation can induce durable remission in heavily pretreated relapsed Hodgkin lymphoma.

Chen R, Palmer JM, Popplewell L, Shen J, Smith E, Delioukina M, Kogut N, Rosenthal J, Forman S, Nademanee A. Chen R, et al. Ann Hematol. 2011 Jul;90(7):803-8. doi: 10.1007/s00277-010-1146-3. Epub 2011 Jan 6. Ann Hematol. 2011. PMID: 21210120

3

Small interfering RNAs targeting cyclin D1 and cyclin D2 enhance the cytotoxicity of chemotherapeutic agents in mantle cell lymphoma cell lines.

Tiemann K, Alluin JV, Honegger A, Chomchan P, Gaur S, Yun Y, Forman SJ, Rossi JJ, Chen RW. Tiemann K, et al. Leuk Lymphoma. 2011 Nov;52(11):2148-54. doi: 10.3109/10428194.2011.593272. Epub 2011 Jul 12. Leuk Lymphoma. 2011. PMID: 21745168 Free PMC article.

4

A phase I study in adults of clofarabine combined with high-dose melphalan as reduced-intensity conditioning for allogeneic transplantation.

Kirschbaum MH, Stein AS, Popplewell L, Delioukina M, Chen R, Nakamura R, Snyder D, Conrad J, Lacey SF, Frankel P, Dagis A, Nademanee A, Forman SJ. Kirschbaum MH, et al. Among authors: chen r. Biol Blood Marrow Transplant. 2012 Mar;18(3):432-40. doi: 10.1016/j.bbmt.2011.07.017. Epub 2011 Jul 27. Biol Blood Marrow Transplant. 2012. PMID: 21801703 Free article. Clinical Trial.

5

Persistence of CD30 expression in Hodgkin lymphoma following brentuximab vedotin (SGN-35) treatment failure.

Nathwani N, Krishnan AY, Huang Q, Kim Y, Karanes C, Smith EP, Forman SJ, Sievers E, Thomas SH, Chen RW. Nathwani N, et al. Leuk Lymphoma. 2012 Oct;53(10):2051-3. doi: 10.3109/10428194.2012.666543. Epub 2012 Apr 18. Leuk Lymphoma. 2012. PMID: 22369501 Free PMC article. No abstract available.

6

Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.

Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Ramchandren R, Bartlett NL, Cheson BD, de Vos S, Forero-Torres A, Moskowitz CH, Connors JM, Engert A, Larsen EK, Kennedy DA, Sievers EL, Chen R. Younes A, et al. Among authors: chen r. J Clin Oncol. 2012 Jun 20;30(18):2183-9. doi: 10.1200/JCO.2011.38.0410. Epub 2012 Mar 26. J Clin Oncol. 2012. PMID: 22454421 Free PMC article. Clinical Trial.

7

Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation.

Gopal AK, Ramchandren R, O'Connor OA, Berryman RB, Advani RH, Chen R, Smith SE, Cooper M, Rothe A, Matous JV, Grove LE, Zain J. Gopal AK, et al. Among authors: chen r. Blood. 2012 Jul 19;120(3):560-8. doi: 10.1182/blood-2011-12-397893. Epub 2012 Apr 17. Blood. 2012. PMID: 22510871 Free PMC article. Clinical Trial.

8

Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma.

Chen R, Palmer JM, Thomas SH, Tsai NC, Farol L, Nademanee A, Forman SJ, Gopal AK. Chen R, et al. Blood. 2012 Jun 28;119(26):6379-81. doi: 10.1182/blood-2012-03-418673. Epub 2012 May 18. Blood. 2012. PMID: 22611160 Free PMC article.

9

Dual functional BAFF receptor aptamers inhibit ligand-induced proliferation and deliver siRNAs to NHL cells.

Zhou J, Tiemann K, Chomchan P, Alluin J, Swiderski P, Burnett J, Zhang X, Forman S, Chen R, Rossi J. Zhou J, et al. Among authors: chen r. Nucleic Acids Res. 2013 Apr;41(7):4266-83. doi: 10.1093/nar/gkt125. Epub 2013 Mar 6. Nucleic Acids Res. 2013. PMID: 23470998 Free PMC article.

10

Management of relapsed or refractory hodgkin lymphoma with second-generation antibody-drug conjugates: focus on brentuximab vedotin.

Mei M, Thomas S, Chen R. Mei M, et al. Among authors: chen r. BioDrugs. 2014 Jun;28(3):245-51. doi: 10.1007/s40259-013-0077-7. BioDrugs. 2014. PMID: 24258497 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

24,746 results

Search Page

Filters